Form 4: Director Michelle McMurry-Heath Executes Bioventus RSU Grant

Director Michelle McMurry-Heath acquired 32,282 shares of Bioventus Class A common stock via RSU vesting and received a new grant of 25,146 RSUs.

Summary

• Director Michelle McMurry-Heath vested 32,282 Restricted Stock Units (RSUs) into Class A common stock on June 2, 2026.
• Following the transaction, the director holds a total of 77,279 shares of Class A common stock.
• On June 3, 2026, the director was granted an additional 25,146 RSUs.
• The new RSU grant is scheduled to vest on the earlier of the day before the next Annual Meeting or the first anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director equity compensation that does not signal a change in company strategy or financial health.

Positives

• Director maintains a significant equity stake of 77,279 shares, aligning interests with shareholders.
• The transaction reflects standard equity compensation practices for board members.

Negatives

• None identified; this is a routine disclosure of equity compensation.

Risks

• Vesting of the new 25,146 RSUs is contingent upon the director continuing service on the Board of Directors.

Future Outlook

The director remains incentivized through a new grant of 25,146 RSUs, which will vest in approximately one year, contingent on continued board service.

Industry Context

StockSavvy.ai notes that routine equity grants to board members are standard practice in the medical device sector to ensure long-term alignment between governance and shareholder value.

Comparison to Industry Standards

• The equity compensation structure is consistent with standard corporate governance practices for mid-cap medical technology companies.
• The vesting schedule aligns with typical annual director compensation cycles observed in the industry.

Stakeholder Impact

• Shareholders benefit from continued director alignment through equity-based compensation.

Next Steps

• Vesting of the 25,146 RSUs granted on June 3, 2026, expected by June 2027 or the next Annual Meeting.

Key Dates

Keywords

Bioventus, BVS, Insider Trading, Form 4, Equity Compensation, Director Ownership